Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanomaM R Middleton, P Friedlander, O Hamid, et al.ESMO Open|October 29, 2021
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-upS P D'Angelo, S Bhatia, A S Brohl, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre studyG A McArthur, M Maio, A Arance, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2024
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyG V Long, M S Carlino, C McNeil, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001O Hamid, C Robert, A Daud, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanomaJ C Hassel, A Arance, M S Carlino, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 18, 2022
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyF Dimitriou, K Namikawa, I L M Reijers, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanomaP Grover, S N Lo, I Li, et al.Pageof 2